Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Good Manufacturing Practices01:26

Good Manufacturing Practices

Good Manufacturing Practices (GMP) constitute a foundational set of guidelines that ensure the production of safe, consistent, and high-quality products, particularly in industries such as pharmaceuticals, biotechnology, and food processing. These protocols encompass all aspects of production, from the sourcing of raw materials to the final distribution of the finished product.A core pillar of GMP is stringent hygiene and sanitation across all production environments. This includes routine...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.

Neurology. Clinical practice·2023
Same author

Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.

Journal of Alzheimer's disease : JAD·2022
Same author

Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.

Cephalalgia : an international journal of headache·2021
Same author

Considerations for applying bioethics norms to a biopharmaceutical industry setting.

BMC medical ethics·2021
Same author

Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study.

Cephalalgia : an international journal of headache·2021
Same author

Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant.

Headache·2020

Related Experiment Video

Updated: Jun 14, 2026

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

Developing good scientific publishing practices: one pharmaceutical company's perspective.

Sherie A Dowsett1, Luann E Van Campen, Lisa A Bednar

  • 1Eli Lilly and Company, Indianapolis, IN 46285, USA. Dowsettsa@lilly.com

Current Medical Research and Opinion
|March 31, 2010
PubMed
Summary

Eli Lilly and Company (Lilly) outlines its transparent publication policies for company-sponsored research. This commitment addresses potential bias in pharmaceutical research to ensure accurate and balanced reporting of drug findings.

More Related Videos

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jun 14, 2026

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
08:29

An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion

Published on: March 31, 2022

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Pharmaceutical industry
  • Medical research
  • Publication ethics

Background:

  • Pharmaceutical companies face scrutiny over potential conflicts of interest in publishing research on their own drugs.
  • Ensuring transparency in scientific publishing is crucial for maintaining public trust.

Purpose of the Study:

  • To share Eli Lilly and Company's (Lilly) principles, policies, and practices for publishing Lilly-sponsored research.
  • To demonstrate Lilly's commitment to transparency in its research activities.

Main Methods:

  • Lilly adheres to its Principles of Medical Research, mandating public disclosure of all medically significant results, whether favorable or unfavorable.
  • Publications involve collaboration between external researchers and Lilly scientists, with shared authorship and responsibility.
  • External authors receive trial data access but are not paid for manuscript development.

Main Results:

  • Lilly ensures accurate, objective, and balanced reporting of research findings, regardless of outcome.
  • Authorship is based on contribution and responsibility, adhering to International Committee of Medical Journal Editors guidelines.
  • Scientific writers at Lilly play a transparent role, contributing expertise and project management, and are acknowledged or listed as authors.

Conclusions:

  • Lilly is committed to appropriate publishing practices in pharmaceutical research.
  • Sharing publication policies fosters dialogue and encourages ethical conduct among stakeholders in drug development.